News

The gene-edited CAR T-cell therapy is currently being investigated in a phase 2 clinical trial.

Tisa-cel was associated with a more favorable safety profile in the analysis.

In this population, median progression-free survival was nearly 40 months.

NKX101 and NKX019 have demonstrated preliminary signs of safety and efficacy in heavily pretreated patients with AML and NHL in 2 separate phase 1 studies.

A phase 1/2 multicenter study is underway following MB-106’s IND approval.

KUR-502 elicited promising response rates for patients with relapsed or refractory B-cell malignancies in a phase 1 study.

The treatment seeks to improve immune reconstitution and graft-versus-leukemia immune response without increasing the risk of GvHD in children and young adults with hematologic malignancies.

Preliminary findings from the phase 1 clinical trial demonstrate good cell persistence and expansion in vivo.

The real-world data support the recently published results from a phase 3 study, which showed most patients achieved transfusion independence.

The greatest improvements were seen in the Pain, Fatigue, and Physical Functioning domains.

In 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.

In this late-breaking poster presented at the Tandem Meetings, investigators recommend that patients with primary or secondary central nervous system lymphoma be included in future clinical trials for CAR T-cell therapy.

Armed with an average of 14.3 months of follow-up data, investigators share updates from a cohort in the phase 2 study evaluating cilta-cel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy at the 2022 Tandem Meetings.

Review top news and interview highlights from the week ending April 15, 2022.

Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm, joins CGTL to discuss the company's development of chimeric co-stimulatory receptor T cells, as well as its clinical programs targeting cancers and infectious diseases.

As patients who undergo CAR T-cell therapy survive longer, more research is required into the long-term neurocognitive effects of this treatment.

The oral therapy is intended for high-risk hematological cancer patients.

Ruhong Jiang, PhD, cofounder, president, and chief executive officer of ASC Therapeutics, joins CGTL to discuss the company's AAV8-based gene therapy for patients with hemophilia A, as well as other pipeline activity.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CT-0508 was granted a fast track designation in September 2021 for use as a potential therapy for patients with solid tumors.

This is the third regenerative medicine advanced therapy designation granted to AlloVir’s posoleucel therapy.

Matt Killeen, PhD, chief scientific officer at Renovacor, shares updates on the company's lead candidate, REN-001, an adeno-associated viral vector serotype 9-based gene therapy for the treatment of BAG3-associated dilated cardiomyopathy.

The FDA has granted a Fast Track Designation to GCC19CART as a potential treatment for adult patients with relapsed and refractory metastatic colorectal cancer.

Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences, joins CGTL to discuss ImmTOR, an immune tolerance platform that could ultimately enable gene therapy redosing in certain cases.

ADI-001 has been granted a Fast Track Designation by the FDA a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

A look at global access to gene therapy and an overview of the progress in hemophilia treatments.

David Apelian, MD, PhD, MBA, chief executive officer at BlueSphere Bio; and Warren Shlomchik, MD, cofounder and scientific advisory board chairman at BlueSphere Bio, join CGTL to discuss the company's leading T-cell therapy clinical program.

The phase 1/2 study (NCT05062980) has officially opened enrollment for patients with late-stage non-small cell lung cancer, with plans to initiate patient screening.

The chief executive officer of Graphite Bio discusses the phase 1/2 CEDAR trial of GPH101, an investigative Cas9-edited autologous CD34+ cell therapy for the treatment of sickle cell disease.

Review top news and interview highlights from the week ending April 15, 2022.